The FDA has approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for the treatment of presbyopia in adults, making it the first dual-agent eye drop approved for age-related near-vision loss. The once-daily drops combine two active ingredients with different mechanisms of action, distinguishing them from previously approved single-agent presbyopia treatments.
Clinical support for the approval came from the phase III BRIO I and BRIO II trials, which demonstrated statistically significant improvements in near vision without compromising distance vision. In BRIO II, patients experienced sustained near-vision improvement for up to eight hours. Reported side effects were generally mild and included headache, temporary vision changes, and eye irritation.
Presbyopia is a common, age-related condition that affects nearly all adults beginning in their mid-40s and impacts millions of individuals in the U.S. While reading glasses, contact lenses, and surgery remain standard management options, pharmacologic treatments for presbyopia are still relatively new. This approval expands the range of non-invasive options available to patients.
Resource: FDA OKs More Eye Drops That Can Replace Reading Glasses